Crews产品代理
Crews产品代理
PROTACs：诱导靶向蛋白质降解
我们的蛋白水解靶向嵌合体 (PROTAC) 技术劫持了细胞质量控制机制，以标记不需要的细胞内蛋白质进行降解。 PROTACs 具有比 siRNA 和 CRISPR 更好的药学特性，通过降解致病蛋白提供了一种新的治疗方式。
For over two decades, the Crews Lab has explored using chemical approaches to control cellular systems. This is best exemplified by the new field of Targeted Protein Degradation and our role in the development of the proteasome inhibitor carfilzomib / Kyprolis® and Proteolysis Targeting Chimera
(PROTACs). We continue to be interested in the design and development of bifunctional small molecules to harness biological systems.
PROTACs: Inducing Targeted Protein Degradation
Our Proteolysis Targeting Chimera (PROTAC) technology hijacks the cellular quality control machinery to tag unwanted intracellular proteins for degradation. With better pharmaceutic properties than siRNA and CRISPR, PROTACs offer a new therapeutic modality by degrading pathogenic proteins.
